Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 208

1.

The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.

Ponti G, Pellacani G, Tomasi A, Gelsomino F, Spallanzani A, Depenni R, Al Jalbout S, Simi L, Garagnani L, Borsari S, Conti A, Ruini C, Fontana A, Luppi G.

J Clin Pathol. 2013 May;66(5):441-5. doi: 10.1136/jclinpath-2012-201345. Epub 2013 Mar 5.

PMID:
23463675
[PubMed - indexed for MEDLINE]
2.

BRAF inhibitor activity in V600R metastatic melanoma.

Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV.

Eur J Cancer. 2013 Mar;49(5):1073-9. doi: 10.1016/j.ejca.2012.11.004. Epub 2012 Dec 10.

PMID:
23237741
[PubMed - indexed for MEDLINE]
3.

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS.

Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1.

PMID:
22588879
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.

Ponti G, Tomasi A, Pellacani G.

J Hematol Oncol. 2012 Oct 2;5:60. doi: 10.1186/1756-8722-5-60.

PMID:
23031422
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D.

Arch Dermatol. 2012 Mar;148(3):357-61. doi: 10.1001/archdermatol.2011.2842. Epub 2012 Jan 16.

PMID:
22250191
[PubMed - indexed for MEDLINE]
6.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
[PubMed - indexed for MEDLINE]
7.

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.

Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG.

Semin Cutan Med Surg. 2012 Dec;31(4):267-73. doi: 10.1016/j.sder.2012.07.007.

PMID:
23174497
[PubMed - indexed for MEDLINE]
8.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R.

J Transl Med. 2010 Jul 14;8:67. doi: 10.1186/1479-5876-8-67.

PMID:
20630094
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Dabrafenib and its potential for the treatment of metastatic melanoma.

Menzies AM, Long GV, Murali R.

Drug Des Devel Ther. 2012;6:391-405. doi: 10.2147/DDDT.S38998. Epub 2012 Dec 11. Review.

PMID:
23251089
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A.

Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7.

PMID:
24508103
[PubMed - indexed for MEDLINE]
11.

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.

Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA, Long GV.

Br J Cancer. 2013 Mar 5;108(4):924-31. doi: 10.1038/bjc.2013.29. Epub 2013 Feb 12.

PMID:
23403819
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.

Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, Lundgren L, Ingvar C, Jönsson G.

Br J Dermatol. 2013 Nov;169(5):1049-55. doi: 10.1111/bjd.12504.

PMID:
23855428
[PubMed - indexed for MEDLINE]
13.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.

Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.

PMID:
24582505
[PubMed - indexed for MEDLINE]
14.

Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.

Flaherty KT.

Clin Exp Metastasis. 2012 Oct;29(7):841-6. doi: 10.1007/s10585-012-9488-y. Epub 2012 Jun 3.

PMID:
22661223
[PubMed - indexed for MEDLINE]
15.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U.

J Clin Oncol. 2013 Sep 10;31(26):3205-11. doi: 10.1200/JCO.2013.49.8691. Epub 2013 Aug 5.

PMID:
23918947
[PubMed - indexed for MEDLINE]
Free Article
16.

Vemurafenib: a guide to its use in unresectable or metastatic melanoma.

Keating GM, Lyseng-Williamson KA.

Am J Clin Dermatol. 2013 Feb;14(1):65-9. doi: 10.1007/s40257-012-0007-3.

PMID:
23329082
[PubMed - indexed for MEDLINE]
17.

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Gibney GT, Zager JS.

Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. Review.

PMID:
23621583
[PubMed - indexed for MEDLINE]
18.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.

PMID:
21343559
[PubMed - indexed for MEDLINE]
Free Article
19.

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.

Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Büttner R, Merkelbach-Bruse S.

BMC Cancer. 2014 Jan 10;14:13. doi: 10.1186/1471-2407-14-13.

PMID:
24410877
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD.

J Clin Oncol. 2013 Feb 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 17.

PMID:
23248257
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk